On July 25, 2016 BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS, reported that it has received two bids that are qualified to participate in the Court authorized auction beginning at 10 a.m. EST on July 25, 2016 (Press release, BIND Therapeutics, JUL 25, 2016, View Source [SID:1234514017]). The bids are in addition to Pfizer Inc.’s initial stalking horse bid of approximately $20 million under Section 363 of the U.S. Bankruptcy Code. Schedule your 30 min Free 1stOncology Demo! The U.S. Bankruptcy Court has authorized BIND to proceed with an auction on July 25, 2016 and the Company intends to select the highest and best offer at the conclusion of the auction. The winning bid is subject to U.S. Bankruptcy Court approval and a hearing is scheduled to take place on July 27, 2016.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BIND initiated voluntary Chapter 11 bankruptcy protection on May 1, 2016 and is conducting a sale of assets pursuant to Section 363 of the Bankruptcy Code.